CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
dexamethasone (50mg 1dd6, 3 consecutive days/month)drug
Likely dose
dexamethasone (50mg 1dd6, 3 consecutive days/month)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00127764
NCT00127764Phase 3Completed

European Randomised Placebo-Controlled Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus (Pempuls Trial)

University Medical Center Groningen·interventional·Posted Aug 8, 2005·Updated Aug 30, 2007

In Brief

A Phase 3 clinical trial evaluating dexamethasone (50mg 1dd6, 3 consecutive days/month) for Pemphigus. Completed, across 1 site.

Detailed Summary

By this study, the investigators want to test if the value of adjuvant pulse glucocorticoid therapy for pemphigus can be determined by comparing an experimental arm (dexamethasone pulse therapy, prednisolone, and azathioprine) with a control arm (placebo pulse therapy, prednisolone, and azathioprine). The investigators will determine the rate of complete remission with dexamethasone pulse therapy; the time needed for complete remission; and the duration of remission, and compare these data with those of the placebo arm.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPemphigus
CountriesNetherlands
Collaborators--

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2005
Enrollment StartJan 1, 2001
Study CompletionApr 1, 2005
TodayJul 2, 2026
Posted 20.9 years ago

Interventions

dexamethasone (50mg 1dd6, 3 consecutive days/month)drug